Controlling cholesterol levels is a major challenge in human health, since hypercholesterolemia can lead to serious cardiovascular disease. Drugs that target carbohydrate metabolism can also modify lipid metabolism and hence cholesterol plasma levels. In this sense, dichloroacetate (DCA), a pyruvate dehydrogenase kinase (PDK) inhibitor, augments usage of the glycolysis-produced pyruvate in the mitochondria increasing oxidative phosphorylation (OXPHOS). In several animal models, DCA decreases plasma cholesterol and triglycerides. Thus, DCA was used in the 70 s to treat diabetes mellitus, hyperlipoproteinemia and hypercholesterolemia with satisfactory results. However, the mechanism of action remained unknown and we describe it here. DCA increases LDLR mRNA and protein levels as well as LDL intake in several cell lines, primary human hepatocytes and two different mouse models. This effect is mediated by transcriptional activation as evidenced by H3 acetylation on lysine 27 on the LDLR promoter. DCA induces expression of the MAPK ERK5 that turns on the transcription factor MEF2. Inhibition of this ERK5/MEF2 pathway by genetic or pharmacological means decreases LDLR expression and LDL intake. In summary, our results indicate that DCA, by inducing OXPHOS, promotes ERK5/MEF2 activation leading to LDLR expression. The ERK5/MEF2 pathway offers an interesting pharmacological target for drug development.
Elevated level of low-density lipoprotein (LDL) in blood is a predominant risk factor for atherosclerosis, a large cause of mortality 1 . Control of plasma cholesterol levels largely depends on low-density lipoprotein receptor (LDLR), which mediates the endocytosis of cholesterol-rich LDL 2, 3 . This process takes place mainly in the liver 2, 3 . LDL is degraded in lysosomes and cholesterol made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis 2, 3 . Hence, LDLR regulates intracellular and extracellular cholesterol homeostasis and is involved in atherosclerosis due to accumulation of LDL-cholesterol in blood 4 . Lipid and carbohydrate metabolic pathways are interconnected and targeting the latter may result in altered cholesterol levels. The pyruvate dehydrogenase (PDH) kinase (PDK) inhibitor dichloroacetate (DCA) activates PDH, the rate-limiting enzyme of aerobic glucose oxidation 5 . PDH converts glycolysis-produced pyruvate in acetyl-CoA that enters the mitochondria and is consumed in the process of oxidative phosphorylation (OXPHOS). Thus, DCA inhibits glycolysis and lactate production and induces OXPHOS [6] [7] [8] [9] [10] . DCA concentration in DCA-treated patients is unclear because its half-life is less than 1 hour and it is not detectable in patients during the initial phase of treatment that can last 2 to 3 months 11, 12 . However, DCA inhibits its own metabolism and serum concentrations increase, eventually reaching a plateau, with plasma concentrations around 0.3 mM 11 . Michelakis et al. gave 50 mg/Kg/day of DCA to patients and obtained similar values: 0.44 ± 0.16 mM 12 . DCA treatment decreases plasma triglyceride and cholesterol in animal models and humans 13, 14 . This effect is likely indirect due to the decrease in plasma of very-low-density lipoproteins (VLDL) by stimulation of triglyceride oxidation 5, 14 , although the mechanism remains unknown. After these findings there was an attempt to use DCA to treat two cases of familial hypercholesterolemia (FH) 15 . DCA reduced circulating cholesterol levels in both patients by decreasing LDL cholesterol 15 . Unfortunately, DCA had to be discontinued following neuropathological effects and this precluded its use to treat high cholesterol levels 15 . The biological mechanism underlying DCA effects on cholesterol was unknown and, to the best of our knowledge, no further studies were conducted to investigate it. Nowadays, the most accepted explanation would be that the change in carbohydrate metabolism alters lipid metabolism. In this sense, DCA, by inhibiting glycolysis, activates AMPK 9 , which inhibits cholesterol synthesis 16, 17 leading to LDLR expression 18, 19 . Enhanced LDLR expression is mediated by a MAPKK because the MAPKK inhibitors PD98059 18 and U0126 20, 21 restrain it. This would indicate that DCA has a similar mechanism of action than the alkaloid berberine and its analogs 18, 19 . An alternative explanation could be that DCA induces ROS production 9, 10 and the cellular oxidative state regulates LDLR expression 22 . Hence, changes in ROS could mediate DCA-induced LDLR expression.
In preliminary experiments, we found by transcriptome analysis that LDLR was one of the most downregulated genes in hematopoietic cells expressing a small hairpin RNA for ERK5 (shERK5) and one of the most upregulated after DCA treatment. We have previously observed that DCA increased mRNA and protein expression of the MAPK ERK5, which is essential for cell survival in OXPHOS conditions 8, 10, [23] [24] [25] [26] . ERK5 activates the MEF2 family of transcription factors [27] [28] [29] [30] that in turn mediates most of the effects of ERK5 on metabolism 8, 10, [23] [24] [25] [26] . In fact, DCA activates multiple genes with promoters containing MEF2 binding sites. Genomic analysis using the UCSC genome browser (http://genome.ucsc.edu/) showed that LDLR is one of such genes because its promoter contains several binding sites for at least two MEF2 proteins, MEF2A and MEF2C, which have been validated in several cell lines by Chromatin Immunoprecipitation (ChIP; (http://genome.ucsc.edu/). We investigate here how DCA reduces cholesterol levels and the role of the ERK5/MEF2 pathway.
Results
DCA enhances LDLR expression. We first observed that DCA increased LDLR mRNA in hematopoietic cells (Fig. 1A, left panel) . Since liver is the main organ that takes up LDL-cholesterol from blood, we tested the effect of DCA in two hepatic cell lines, finding that LDLR mRNA levels were also increased (Fig. 1A, right panel) . Augmented LDLR mRNA levels correlated with an increase of LDLR protein in the plasma membrane ( Fig. 1B and Supplemental Fig. 1A ). We then tested the functional consequence of this enhanced expression by incubating control or DCA-treated cells with fluorescently labeled LDL. DCA increased LDL transport into these cell lines ( Fig. 1C and Supplemental Fig. 1B ).
Cells performing OXPHOS increase LDLR activity. DCA induces OXPHOS in leukemic cells 8-10, 24, 25, 31 . To investigate whether the metabolic switch from aerobic glycolysis to OXPHOS mediated by DCA affect LDLR expression, we used a glucose-free culture medium containing a final glutamine concentration of 4 mM and 10 mM galactose. Glutamine is used to drive mitochondria to utilize OXPHOS and galactose allows cells to synthesize nucleic acids through the pentose phosphate pathway 8, 24, 32, 33 . We called it 'OXPHOS medium' because it forced leukemic cells to use OXPHOS as primary ATP source 8, 9, 23 . We observed that acute myeloid leukemia (AML) OCI-AML3 cells growing in OXPHOS medium for 2 weeks, such as those treated with DCA, presented an increase of ERK5 and LDLR mRNA (Supplemental Fig. 2A ), LDLR protein and LDL intake (Fig. 1D) . These results indicated that, as expected, the effect of DCA on LDLR expression was due to a metabolic switch. DCA and OXPHOS also increased LDLR mRNA and protein as well as LDL intake in primary lymphoma cells derived from a B cell lymphoma patient (BCL-P2; Fig. 1A, Supplemental Fig. 1B and Fig. 1E ). We found similar results in the hepatic cell lines HepG2-C3A and HuH7, with OXPHOS media increasing LDLR protein and uptake (Supplemental Fig. 3) .
In primary human hepatocytes, DCA also induced LDLR expression at 6 and 24 h post treatment ( Fig. 2A) . However, effects disappeared at 48 and 72 h with a net decrease ( Fig. 2A) . This is likely due to the short DCA half-life, since LDLR mRNA levels were kept high when fresh DCA was added to the medium every 24 h (Fig. 2B ).
Reactive Oxygen Species (ROS) do not mediate DCA-induced LDLR expression. The cellular oxidative state can regulate LDLR expression 22 and DCA induces ROS production in certain hematopoietic cell lines but not in others 9, 10 . We observed a similar phenomenon in two different hepatic cell lines. In Huh7 cells there was an increase of ROS, but not in HepG2-C3A cells, after DCA treatment (Fig. 3A) . In contrast, in all cell lines utilized in this study, DCA increased LDLR expression, suggesting that ROS production was not essential (Figs 1A and 3B). Next, we incubated both hepatic cell lines with the antioxidant N-acetyl-cysteine (NAC). NAC efficiently blocked DCA-induced ROS production in HuH7 cells (Fig. 3A) ; however, it did not affect DCA-induced LDLR mRNA (Fig. 3B ) or plasma membrane protein (Fig. 3C ). To definitively exclude that ROS played any role in LDLR induction, we incubated primary hepatocytes with DCA in presence or absence of NAC. We found that NAC did not inhibit and in fact increased LDLR mRNA expression (Fig. 3D) . These results exclude a major role for de novo ROS production in LDLR expression after DCA treatment.
DCA induces LDLR in vivo.
We next assessed whether DCA enhances LDLR expression in vivo. We engrafted human AML primary cells in non-obese diabetic/severe combined immunodeficient (NOD/ SCID)-interleukin-2 receptor γ chain null (NSG) mice, as previously described 9, 10 . Mice with established tumors (day 80 post-graft) were treated daily with DCA (Fig. 4A) . The treatment was not toxic and did not show any The bar graphs represent means ± SD of 3 independent experiments performed in triplicate; *p < 0.05, **p < 0.01, ***p < 0.005 student t-test compared to control cells. notable effect on mice survival 9 . Human tumor AML cells gather in murine spleen and bone marrow, hence we isolated mRNA from these organs. We used human-specific primers and observed that DCA significantly increased expression of LDLR mRNA (Fig. 4A) .
We also found augmented mouse LDLR mRNA levels in normal liver and spleen from wt mice that were treated daily, for 1 and up to 3 days, with DCA (Fig. 4B) . The effect was first observed in hematopoietic cells by FACs for ROS production. LDLR mRNA (B) or protein (C) from these cells were analyzed as described in Fig. 1 . Results represent the means ± SD of these donors with experiments performed in triplicate. The data represent means ± SD; *p < 0.05, **p < 0.01, ***p < 0.005 student t-test compared to cells non treated with DCA. D) Primary hepatocytes from 2 independent donors were treated for 6 and 24 h as in (A) but with two different DCA concentrations before analyzing LDLR mRNA expression. The data represent means ± SD; *p < 0.05, **p < 0.01, ***p < 0.005 one-way ANOVA with post-hoc Tukey test.
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LDLR expression requires MEF2. ERK5 mediates part of its metabolic functions through the MEF2 family of transcription factors 8, 10, 23, 24 . Interestingly, LDLR promoter contains predicted binding sites for MEF2A and C that have been validated in several cell lines (http://genome.ucsc.edu/). Therefore, we performed a knockdown of MEF2A and C in OCI-AML3 cells by siRNA. These siRNA halved mRNA expression of both transcription factors (Fig. 7A) and reduced between 25 and 50% protein levels (Supplemental Fig. 4C ). The level of knockdown was sufficient to significantly decrease LDLR mRNA levels (Fig. 7A) . Finally, to further investigate whether DCA activated LDLR promoter, we checked the Histone H3 lysine 27 acetylation (H3K27Ac), a modification associated with active gene expression 39 . We observed that H3K27Ac increased after DCA treatment indicating an increase of LDLR gene transcription (Fig. 7B) .
The ERK5/MEF2 pathway also controls expression of the LDL receptor-adapter protein 1 (LDLRAP1).
The LDL receptor-adapter protein 1 (LDLRAP1) is a cytosolic protein that interacts with the cytoplasmic tail of LDLR 40 . LDLRAP1 promoter contains MEF2 binding sites (http://genome.ucsc.edu/), suggesting that the same ERK5/MEF2 pathway could regulate this gene. Consequently with this hypothesis, DCA enhanced LDLRAP1 expression in hepatic cell lines and primary hepatocytes (Fig. 8A) . OCI-AML3 and primary tumor B cells also increased LDLRAP1 mRNA after DCA treatment or after incubation in OXPHOS medium (Fig. 8B) . In non-stimulated cells, siERK5 reduced LDLRAP1 mRNA in primary hepatocytes, Huh7 cells and primary tumor cells (Fig. 8C (left), Supplementary Fig. 5C ). Similarly, OCI-AML3 cells transfected with siMEF2 repressed the expression of LDLRAP1 mRNA (Fig. 8C (right) . In summary, cells performing OXPHOS increased the expression of an additional protein involved in LDLR activity.
Discussion
Carbohydrate and lipid metabolism are intrinsically bound and their dysfunction play a major role in cardiovascular disease. Diabetes is typically associated to dyslipidemia, but vice versa, lipid changes also disturb glucose metabolism 41 . DCA, by stimulating PDH activity, decreases glucose catabolism and stimulates OXPHOS 6, 7 . To fuel it, cells could rely on fatty acid oxidation (FAO), suggesting that DCA could increase lipid catabolism. LDL particles transport cholesterol and triglycerides; hence an increase in LDLR should allow cells to increase fat availability. We propose that the avidity for fatty acids induces DCA-treated cells to increase LDLR expression and, subsequently, cholesterol uptake. This is supported by our observations showing that OXPHOS, which mediates FAO, reproduces DCA effects on LDLR expression in vitro ( Fig. 1 and Supplemental Figs 2 and 3) . The mechanism requires ERK5, which directs the choice of catabolic substrates 8, 10, [23] [24] [25] [26] and, hence, is a good candidate to control increase on fat avidity. Inhibiting ERK5 function by pharmacological or genetic means decrease LDL intake (Fig. 5) . This reduces the consumption of exogenous cholesterol but should also affect the consumption of fatty acids. In contrast, in vivo ERK5 stimulation, e.x; by DCA treatment, induces LDLR mRNA (Fig. 4) and would induce triglyceride oxidation as previously observed 5, 14 . The ERK5 target MEF2 also regulates this pathway, likely because LDLR promoter contains MEF2 binding sites (see Introduction). ERK5 induces activation of several members of the MEF2 family of transcription factors by several mechanisms. It induces direct phosphorylation at different serines and threonines on MEF2A, C and D 27, 28 . It can also activate MEF2A and D by direct interaction because ERK5 serves as a MEF2 coactivator through its signal-dependent direct association with the MEF2 MADS domain. Although, at least MEF2A-dependent transcription requires ERK5 kinase activity 29, 30 . MEF2 mediates several ERK5 effects on metabolism 10 . However, the exact mechanism via which DCA stimulates LDLR expression could be multifactorial, although it is a general phenomenon that we have confirmed in several hematopoietic, colon and hepatic cells (Fig. 1) , including primary human hepatocytes (Fig. 2) , which are the main regulators of cholesterol levels 2, 3 . We cannot exclude that other mechanisms play a role in DCA-induced LDLR expression. For example, DCA inhibits HMG CoA reductase activity in liver and leukocytes 6 . This could lead to an even higher demand on exogenous cholesterol and subsequently to an increase in LDLR levels. In addition, we have also recently shown that the MAPK ERK5 induces Sirt1 expression 24 that also stabilizes LDLR protein 42 . Therefore, ERK5 could target LDLR function in multiple ways and some of them independently of MEF2 family. In contrast, we have mainly excluded that ROS levels or AMPK activation play a major role in this process (Figs 3 and 6) .
Other drugs could modulate the ERK5/MEF2 pathway to regulate the expression of LDLR. Berberine induces LDLR expression by a MAPK pathway sensitive to PD98059 18 and U0126 20, 21 , two inhibitors that block the ERK5 pathway 37 . Then, ERK5 could also partly mediate berberine effects, although independently of AMPK (Fig. 6) . DCA decreases cholesterol plasma levels in several animal models and humans 5, [13] [14] [15] . In this study, we have mainly used high (10 mM) DCA concentrations for acute responses and "physiological" concentrations (1 to 5 mM) for chronic treatments. These latter values are in the range of those used in DCA-treated patients 11, 12 . Michelakis et al. gave 50 mg/Kg/day of DCA to patients 12 . On average, this amount of DCA should give a blood concentration of 4.6 mM, i.e. by considering 70 Kg/patient and a total of 5 L of blood. However, DCA plasma concentration was around 0.4 mM 11, 12 and the ultimate destination of the DCA that was not in blood was unknown. Perhaps the liver processes DCA very fast as suggested by our results using primary hepatocytes (Fig. 2) . There was an attempt to use DCA for treating hypercholesterolemia using similar DCA doses to ours in vivo 15 . DCA reduced circulating cholesterol levels in two patients through a mechanism involving a reduction in LDL cholesterol 15 , although both patients initially showed low LDLR surface activity. However, DCA was halted due to its neuropathological effects 15 and this precluded its use to treat high cholesterol. These pathological effects have been observed in other clinical contexts, e.g. lactic acidosis and stroke-like episodes (MELAS) 43 . At the beginning of their DCA treatment, patients quickly eliminate DCA 11, 12 . In this manuscript, we have observed that in primary hepatocytes fresh DCA should be daily added to media to keep physiological effects (Fig. 2) . As expected, hepatocytes probably metabolize DCA faster than other cell types 6 . After several weeks of treatment, DCA plasma concentrations reach a plateau around 0.4 mM 11, 12 , and during this phase neuropathology appears 11 . From a pharmaceutical point of view, it would be desirable to use drugs with the LDLR-stimulating effect of DCA, but without its neuropathological effects. The uncovering of ERK5/MEF2 pathway as a regulator of LDLR expression opens an interesting pharmacological possibility. OCI-AML3 cells were incubated for 72 h with 10 mM DCA. Cells were prepared for ChIP analysis using an antibody against H3 acetylation on lysine 27. Acetylation was revealed at different points of the LDLR promoter by using specific oligonucleotides. Bar graphs represent means ± SD; *p < 0.05, **p < 0.01, ***p < 0.005 student t-test compared to empty vector transfected cells (control). 
Methods
Ethical statement. Experimental procedures were conducted according to the European guidelines for animal welfare (2010/63/EU). Protocols were approved by the Animal Care and Use Committee "LanguedocRoussillon" (approval number: CEEA-LR-12163). The use of human specimens for scientific purposes was approved by the French National Ethics Committee. All methods were carried out in accordance with the approved guidelines and regulations of this committee. Written informed consent was obtained from each patient prior to surgery.
In vivo mouse experiments. In vivo experiments were carried out using 6 to 8 weeks/old male NSG mice. Mice were bred and housed in pathogen-free conditions in the animal facility of the European Institute of Oncology-Italian Foundation for Cancer Research (FIRC), Institute of Molecular Oncology (Milan, Italy). For engraftment of human cells, 1 million AML cells were injected intravenously (i.v.) through the lateral tail vein in non-irradiated mice. NSG mice with established human AML tumors (day 80 post-graft) were treated with DCA (50 mg/kg, 1 dose/day by gavage, starting at day 1 for 16 consecutive days). Human tumor AML cells gather in mouse spleen and bone marrow, hence we isolated mRNA from these organs. We used human-specific primers to visualize expression of human LDLR mRNA. In a different experiment B6 wt mice were treated with a daily single dose of DCA (50 mg/kg/day) intraperitoneally and mouse LDLR mRNA was analyzed in spleen and liver at different time points.
Cell lines and culture conditions. The leukemic human cell lines T Jurkat TAg and OCI-AML3 were grown in RPMI 1640-Glutamax (GIBCO) supplemented with 5% (Jurkat) or 10% (OCI-AML3) FBS 10, 24 . Primary cells from a lymphoma B cell patient (BCL-P2) were grown in the same medium with 10% FBS. In certain experiments cells were grown in RPMI 1640 without glucose (GIBCO 11879) with the addition of 2 mM glutamine and 10 mM galactose (OXPHOS medium). The Jurkat TAg cells carry the SV40 large T Ag to facilitate cell transfection. HepG2-C3A and HuH7 cells were grown in MEM and DMEM respectively supplemented with FBS, sodium pyruvate, glutamine, penicillin and streptomycin. The HCT116 human colon cancer cells were cultured in low glucose (5 mM) DMEM medium supplemented with 10% FBS. Cellular confluence during experiments was between 80-85%.
Human liver samples and preparation of PHHs cultures. Liver samples were obtained from liver resections performed in adult patients for medical reasons. Human hepatocytes isolation and culture were performed as described previously 44 . Briefly, after liver perfusion, hepatocytes were counted and cell viability was assessed by trypan blue exclusion test. A suspension of 1 × 10 6 cells/mL per well was added in 12-well plates pre-coated with type I collagen (Beckton Dickinson) and cells were allowed to attach for 12 h. Then, the supernatant containing dead cells and debris was carefully removed and replaced with 1 mL of serum-free long-term culture medium (Lanford medium, LNF). The number of confluent attached cells was estimated at ~1. Reagents and antibodies. DCA was from Santa Cruz Technologies. Galactose and glutamine were from GIBCO. Human anti-LDLR-PE and IgG were from BD Biosciences and 7AAD from Beckman. The MEK5 inhibitor BIX02189 and the ERK5 inhibitor XMD8-92 were from Selleck. RIPA buffer to prepare protein extracts was from Euromedex. The complete protease inhibitor cocktail (Complete EDTA-free) and the phosphatase inhibitor cocktail (PhosSTOP) were from Roche. ERK5 and MEF2A/C antibodies were from Cell Signaling Technology and Abcam respectively. The antibody against β-Actin and HRP-labeled secondary antibodies were from Sigma.
Transient transfection. Jurkat cells in logarithmic growth phase were transfected with the indicated amounts of plasmid by electroporation 45, 46 . In each experiment, cells were transfected with the same total amount of DNA by supplementing with empty vector. Cells were incubated for 10 min at RT with the DNA mix and electroporated using the Gene Pulser Xcell ™ Electroporation system (Bio-Rad) at 260 mV, 960 mF in 400 µl of RPMI 1640. Expression of the different proteins was confirmed by western blot. The transfection efficiency in Jurkat TAg cells is between 60 and 80%. OC-AML-3 cells were transfected using Amaxa TM D-Nucleofector TM Lonza Kit according to manufactured protocol. In HuH7 and HCT116 cells, transfection of 30-50 nM siRNAs was carried out using Lipofectamine RNAiMAX (Invitrogen) in Opti-MEM (Invitrogen), according to the manufacturer's instructions. Primary hepatocytes were transfected twice at days 1 and 3 post-seeding. Cells were harvested 48 to 96 h post-transfection.
Plasmids. The expression vectors for ERK5, the pSUPER expression vector for GFP alone or GFP plus shERK5 and the pSiren-retroQ-puro (BD Biosciences) retroviral vectors for shERK5 and control have been previously described 45 . Control, MEF2A and C and ERK5 siRNA were ON-TARGETplus SMARTpools (mixture of 4 siRNA) were from Dharmacon.
Counting and determination of cell viability. Cell 
